Colon Cancer Studies

The Cancer Institute collaborates with Benaroya Research Institute and the Digestive Disease Institute to offer colon cancer studies.

• A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III
   
• Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer
   
• NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: The NEO Trial
   

• STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR.

  
   

If you would like to talk with a clinical research coordinator about clinical research trials related to pancreas cancer, call the Cancer Clinical Research Unit Research hotline at (206) 342-6954.